[시장보고서]세계의 괴사성 근막염 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 치료법별, 유통 채널별, 지역별 부문 예측(2025-2033년)

세계의 괴사성 근막염 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 치료법별, 유통 채널별, 지역별 부문 예측(2025-2033년)

Necrotizing Fasciitis Market Size, Share & Trends Analysis Report By Type, By Treatment, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1869587

리서치사 : Grand View Research

발행일 : 2025년 10월

페이지 정보 : 영문 100 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,710,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,174,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,102,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

괴사성 근막염 시장 요약

세계의 괴사성 근막염 시장 규모는 2024년 10억 2,724만 달러였고, 2033년까지 20억 9,781만 달러에 이를 것으로 예측됩니다.

2025년부터 2033년까지 CAGR 8.3%로 성장이 예상됩니다. 이 시장의 성장은 몇 가지 주요 요인 때문입니다. 이 질병의 심각성과 급속한 진행에 대한 인식이 증가함에 따라 효과적인 치료에 대한 수요가 증가하고 있습니다.

의료기술의 진보와 혁신적인 항생제 및 외과적 개입법의 보급으로 환자의 예후가 개선되어 시장 확대를 더욱 촉진하고 있습니다. 괴사성 근막염(NF)은 혈류가 제한된 근막 평면을 따라 퍼지는 심각한 피부 및연부 조직 감염증입니다. 초기 단계에서는 표면 조직에 영향을 미치지 않는 경우가 많으며 진단과 치료가 지연되는 경향이 있습니다. 진행에 따라 근막, 근막 주위 평면, 주위 피부, 연부 조직, 근육에 걸릴 수 있습니다. 미국에서는 연간 약 100,000명당 0.4명이 앓고 있으며, 일부 지역에서는 10만명당 1명이라는 보고도 있습니다.

게다가 당뇨병, 비만, 면역 결핍 상태 등 위험인자의 유병률 상승이 증례 수 증가에 기여하고 있습니다. 국제 당뇨병 연합에 따르면 2024년에는 당뇨병이 340만명의 사망 원인이었고, 이는 9초에 1명의 비율에 해당합니다. 또한 세계 5억 8,900만 명의 성인(20-79세)이 이 질환을 안고 생활하고 있습니다. 이 증가하는 당뇨병 환자 수는 괴사성 근막염에 걸리는 위험을 현저하게 높여 전문 의료에 대한 수요를 촉진하고 있습니다. 또한 의료 서비스 제공업체의 조기 진단 및 치료에 대한 관심 증가와 의료비 지출 증가가 함께 시장의 꾸준한 성장을 지원하고 있습니다.

치료별 시장 점유율, 2024년 및 2033년
치료별 부문 대시보드
시장 규모와 예측 및 동향 분석, 치료별, 2021-2033년
경험적 광역 항균제
MRSA 보상의 추가 옵션
침습성 GAS에 대한 항독소 보조제
병원체 표적 항균 요법
괴사성 진균 감염에 대한 항진균제
면역요법

제6장 괴사성 근막염 시장 : 유통 채널별 비즈니스 분석

유통 채널별 시장 점유율, 2024년 및 2033년
유통 채널별 부문 대시보드
시장 규모, 예측, 동향 분석, 유통 채널별, 2021-2033년
병원 약국
소매 약국
온라인 약국

제7장 괴사성 근막염 시장 : 지역별 추정 및 동향 분석

지역별 시장 점유율 분석, 2024년 및 2033년
지역별 시장 대시보드
시장 규모와 예측 동향 분석, 2021-2033년:
북미
- 국가별, 2021-2033년
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

참가자 개요
기업의 시장 포지셔닝 분석
기업 분류
전략 매핑
기업 프로파일
- Pfizer Inc.
- Merck & Co., Inc.(MSD)
- Gilead Sciences
- Astellas Pharma
- Basilea Pharmaceutica
- CSL Behring
- Takeda
- Grifols
- Octapharma
- Hikma Pharmaceuticals

JHS

영문 목차

영문목차

Necrotizing Fasciitis Market Summary

The global necrotizing fasciitis market size was estimated at USD 1,027.24 million in 2024 and is projected to reach USD 2,097.81 million by 2033, growing at a CAGR of 8.3% from 2025 to 2033. The market is experiencing growth due to several key factors. Increasing awareness about the severity and rapid progression of the disease has led to a higher demand for effective treatments.

Advances in medical technology and the availability of innovative antibiotics and surgical interventions improve patient outcomes, further driving market expansion. Necrotizing Fasciitis (NF) is a serious skin and soft tissue infection that spreads along fascial planes with limited blood supply. It often leaves overlying tissues initially unaffected and delays diagnosis and treatment. As it progresses, it can involve fascia, peri-fascial planes, surrounding skin, soft tissue, and muscle. The condition affects around 0.4 per 100,000 people in the U.S. annually, with some areas reporting up to 1 per 100,000.

In addition,the rising prevalence of risk factors such as diabetes, obesity, and immunocompromised conditions is contributing to a greater number of cases. According to the International Diabetes Federation, diabetes was responsible for 3.4 million deaths in 2024, equivalent to one death every nine seconds, and 589 million adults (aged 20-79 years) are living with the condition worldwide. This rising diabetic population significantly increases the susceptibility to Necrotizing Fasciitis, fueling the demand for specialized care. Moreover, the growing focus of healthcare providers on early diagnosis and treatment, along with increased healthcare spending, is supporting the market's steady growth.

Global Necrotizing Fasciitis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global necrotizing fasciitis market report based on type, treatment, distribution channel, and region:

Type Outlook (Revenue, USD Million, 2021 - 2033)
Type I (Polymicrobial)
Type II (Monomicrobial)
Type III (Gas gangrene / clostridial myonecrosis)
Treatment Outlook (Revenue, USD Million, 2021 - 2033)
Empiric broad-spectrum antibacterials
MRSA-coverage add-ons
Antitoxin adjunct for invasive GAS
Pathogen-targeted antibacterial regimens
Antifungals for necrotizing fungal infections
Immunotherapies
Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Treatment
- 1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Necrotizing Fasciitis Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis

Chapter 4. Necrotizing Fasciitis Market: Type Business Analysis

4.1. Type Market Share, 2024 & 2033
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 - 2033 (USD Million)
4.4. Type I (Polymicrobial)
- 4.4.1. Type I (Polymicrobial) market estimates & forecasts, 2021 - 2033 (USD Million)
4.5. Type II (Monomicrobial)
- 4.5.1. Type II (Monomicrobial) market estimates & forecasts, 2021 - 2033 (USD Million)
4.6. Type III (Gas gangrene / clostridial myonecrosis)
- 4.6.1. Type III (Gas gangrene / clostridial myonecrosis) market estimates & forecasts, 2021 - 2033 (USD Million)

Chapter 5. Necrotizing Fasciitis Market: Treatment Business Analysis

5.1. Treatment Market Share, 2024 & 2033
5.2. Treatment Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
5.4. Empiric broad-spectrum antibacterials
- 5.4.1. Empiric broad-spectrum antibacterials market estimates & forecasts, 2021 - 2033 (USD Million)
5.5. MRSA-coverage add-ons
- 5.5.1. MRSA-coverage add-ons market estimates & forecasts, 2021 - 2033 (USD Million)
5.6. Antitoxin adjunct for invasive GAS
- 5.6.1. Antitoxin adjunct for invasive GAS market estimates & forecasts, 2021 - 2033 (USD Million)
5.7. Pathogen-targeted antibacterial regimens
- 5.7.1. Pathogen-targeted antibacterial regimens market estimates & forecasts, 2021 - 2033 (USD Million)
5.8. Antifungals for necrotizing fungal infections
- 5.8.1. Antifungals for necrotizing fungal infections market estimates & forecasts, 2021 - 2033 (USD Million)
5.9. Immunotherapies
- 5.9.1. Immunotherapies market estimates & forecasts, 2021 - 2033 (USD Million)

Chapter 6. Necrotizing Fasciitis Market: Distribution Channel Business Analysis

6.1. Distribution Channel Market Share, 2024 & 2033
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
6.4. Hospital Pharmacies
- 6.4.1. Hospital pharmacies market estimates & forecasts, 2021 - 2033 (USD Million)
6.5. Retail Pharmacies
- 6.5.1. Retail pharmacies market estimates & forecasts, 2021 - 2033 (USD Million)
6.6. Online pharmacies
- 6.6.1. Online pharmacies market estimates & forecasts, 2021 - 2033 (USD Million)

Chapter 7. Necrotizing Fasciitis Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
- 7.4.1. North America necrotizing fasciitis market estimates & forecasts, by country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Type disease prevalence
  - 7.4.2.3. Regulatory framework
  - 7.4.2.4. Reimbursement framework
  - 7.4.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Type disease prevalence
  - 7.4.3.3. Regulatory framework
  - 7.4.3.4. Reimbursement framework
  - 7.4.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
  - 7.4.4.1. Key country dynamics
  - 7.4.4.2. Type disease prevalence
  - 7.4.4.3. Regulatory framework
  - 7.4.4.4. Reimbursement framework
  - 7.4.4.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
7.5. Europe
- 7.5.1. Europe necrotizing fasciitis market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Type disease prevalence
  - 7.5.2.3. Regulatory framework
  - 7.5.2.4. Reimbursement framework
  - 7.5.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Type disease prevalence
  - 7.5.3.3. Regulatory framework
  - 7.5.3.4. Reimbursement framework
  - 7.5.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Type disease prevalence
  - 7.5.4.3. Regulatory framework
  - 7.5.4.4. Reimbursement framework
  - 7.5.4.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Type disease prevalence
  - 7.5.5.3. Regulatory framework
  - 7.5.5.4. Reimbursement framework
  - 7.5.5.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key country dynamics
  - 7.5.6.2. Type disease prevalence
  - 7.5.6.3. Regulatory framework
  - 7.5.6.4. Reimbursement framework
  - 7.5.6.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
  - 7.5.7.1. Key country dynamics
  - 7.5.7.2. Type disease prevalence
  - 7.5.7.3. Regulatory framework
  - 7.5.7.4. Reimbursement framework
  - 7.5.7.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
  - 7.5.8.1. Key country dynamics
  - 7.5.8.2. Type disease prevalence
  - 7.5.8.3. Regulatory framework
  - 7.5.8.4. Reimbursement framework
  - 7.5.8.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
  - 7.5.9.1. Key country dynamics
  - 7.5.9.2. Type disease prevalence
  - 7.5.9.3. Regulatory framework
  - 7.5.9.4. Reimbursement framework
  - 7.5.9.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific necrotizing fasciitis market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.6.2. China
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Type disease prevalence
  - 7.6.2.3. Regulatory framework
  - 7.6.2.4. Reimbursement framework
  - 7.6.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.6.3. Japan
  - 7.6.3.1. Key country dynamics
  - 7.6.3.2. Type disease prevalence
  - 7.6.3.3. Regulatory framework
  - 7.6.3.4. Reimbursement framework
  - 7.6.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
  - 7.6.4.1. Key country dynamics
  - 7.6.4.2. Type disease prevalence
  - 7.6.4.3. Regulatory framework
  - 7.6.4.4. Reimbursement framework
  - 7.6.4.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
  - 7.6.5.1. Key country dynamics
  - 7.6.5.2. Type disease prevalence
  - 7.6.5.3. Regulatory framework
  - 7.6.5.4. Reimbursement framework
  - 7.6.5.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
  - 7.6.6.1. Key country dynamics
  - 7.6.6.2. Type disease prevalence
  - 7.6.6.3. Regulatory framework
  - 7.6.6.4. Reimbursement framework
  - 7.6.6.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
  - 7.6.7.1. Key country dynamics
  - 7.6.7.2. Type disease prevalence
  - 7.6.7.3. Regulatory framework
  - 7.6.7.4. Reimbursement framework
  - 7.6.7.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
7.7. Latin America
- 7.7.1. Latin America necrotizing fasciitis market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Type disease prevalence
  - 7.7.2.3. Regulatory framework
  - 7.7.2.4. Reimbursement framework
  - 7.7.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key country dynamics
  - 7.7.3.2. Type disease prevalence
  - 7.7.3.3. Regulatory framework
  - 7.7.3.4. Reimbursement framework
  - 7.7.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
7.8. Middle East and Africa
- 7.8.1. Middle East and Africa necrotizing fasciitis market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key country dynamics
  - 7.8.2.2. Type disease prevalence
  - 7.8.2.3. Regulatory framework
  - 7.8.2.4. Reimbursement framework
  - 7.8.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key country dynamics
  - 7.8.3.2. Type disease prevalence
  - 7.8.3.3. Regulatory framework
  - 7.8.3.4. Reimbursement framework
  - 7.8.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key country dynamics
  - 7.8.4.2. Type disease prevalence
  - 7.8.4.3. Regulatory framework
  - 7.8.4.4. Reimbursement framework
  - 7.8.4.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Key country dynamics
  - 7.8.5.2. Type disease prevalence
  - 7.8.5.3. Regulatory framework
  - 7.8.5.4. Reimbursement framework
  - 7.8.5.5. Market estimates & forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
- 8.5.1. Pfizer Inc.
  - 8.5.1.1. Overview
  - 8.5.1.2. Financial Performance
  - 8.5.1.3. Product Benchmarking
  - 8.5.1.4. Strategic Initiatives
- 8.5.2. Merck & Co., Inc. (MSD)
  - 8.5.2.1. Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Product Benchmarking
  - 8.5.2.4. Strategic Initiatives
- 8.5.3. Gilead Sciences
  - 8.5.3.1. Overview
  - 8.5.3.2. Financial Performance
  - 8.5.3.3. Product Benchmarking
  - 8.5.3.4. Strategic Initiatives
- 8.5.4. Astellas Pharma
  - 8.5.4.1. Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Product Benchmarking
  - 8.5.4.4. Strategic Initiatives
- 8.5.5. Basilea Pharmaceutica
  - 8.5.5.1. Overview
  - 8.5.5.2. Financial Performance
  - 8.5.5.3. Product Benchmarking
  - 8.5.5.4. Strategic Initiatives
- 8.5.6. CSL Behring
  - 8.5.6.1. Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Product Benchmarking
  - 8.5.6.4. Strategic Initiatives
- 8.5.7. Takeda
  - 8.5.7.1. Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Product Benchmarking
  - 8.5.7.4. Strategic Initiatives
- 8.5.8. Grifols
  - 8.5.8.1. Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Product Benchmarking
  - 8.5.8.4. Strategic Initiatives
- 8.5.9. Octapharma
  - 8.5.9.1. Overview
  - 8.5.9.2. Financial Performance
  - 8.5.9.3. Product Benchmarking
  - 8.5.9.4. Strategic Initiatives
- 8.5.10. Hikma Pharmaceuticals
  - 8.5.10.1. Overview
  - 8.5.10.2. Financial Performance
  - 8.5.10.3. Product Benchmarking
  - 8.5.10.4. Strategic Initiatives